In the morning of March 16, the Special Promotion conference for Academician Chen Pu, which was the first special promotion conference for academician project products after the Spring Festival, was successfully held in Qingdao International Academician Park. During the campaign, 11 enterprises signed cooperation contracts worth 4.9 billion yuan on biopharmaceutical products, construction and operation of industrial platforms and other projects; 22 enterprises and the academician team yielded cooperation initiatives worth 11 billion yuan on scare removal, polypeptide siRNA and other projects. Qingdao International Academician Park has made progress in promoting industrial application of results. 

Ji Mingtao, a member of the standing committee of the Party Committee of Licang District and director of the Party Committee Office of Licang District, delivered a speech. 

During the promotion conference, Academician Chen Pu explained research results and products of his team in person. Zhuo Lang, vice president of NanoPeptide (Qingdao) Biotechnology Ltd., further explained product functions and effects, the actual application of the siRNA technology, antimicrobial peptides, etc. in particular. The products have a broad market. It is predicted that the market demand for scar removal will reach 237 billion yuan in 2023.

Pharmaceutical enterprises and financial institutions were attracted to attend the promotion conference.

The promotion conference attracted more than 210 people from 133 pharmaceutical enterprises (including 9 listed enterprises like Tongrentang), 10 financial institutions, 17 media, 13 scientific research institutions and medical institutions, 6 e-commerce enterprises and 10 government departments.

Academician Chen Pu explained research results and products of his team in person.

Academician Chen Pu is a member of the Canadian Academy of Engineering and a chief professor in Canada's nanoscale biological manufacturing. He is an international well-known expert in biological nanomaterials, nanomedicine, environmental science, interfacial thermodynamics, energy and other interdisciplinary research fields. This promotion conference mainly recommended and exhibited polypeptide antibiotics and other relevant techniques and products which Academician Chen Pu has researched for years.

1. How big will the anticipated scar removal market be?

According to official statistic data, the global market value was 130 billion yuan in 2017; it is predicted that it will reach 237 billion yuan in 2023, an annual increase of over 10%. At present, the traditional treatments for hyperplastic scars are mostly surgery, laser and ointment but it is easy to cause new scars during treatment. FDA doesn't have effective drugs for treating hyperplastic scars either. Therefore, once the technical problems are solved, there will be huge profits. 

2. The Safety Issues of Gene Therapy

There’re lots of gene therapy. We adopt siRNA drugs which won’t modify the genome of target cells, aren't hereditary and can be metabolized normally by cells. In addition, the siRNA sequence is highly specific towards target genes but won't affect other genes. On the other hand, our independently developed carriers are nanopeptide carriers which are a kind of highly safe carriers in human bodies. 

3. Are nanopeptide carriers a kind of carriers or a series of carriers? Will it be applied jointly with siRNA?

We have developed a series of nanopeptide carriers for different target tissues and cells. We will make an application by taking nanopeptide carriers and siRNA as a whole.

4. What is the technical core of the PDO?

The three-dimensional PDO models cultured in vitro simulate the in vivo tumor microenvironment structurally while keeping consistent with the genetic information of patients’ tumor tissues, thus replacing patients in testing drugs. They can be used to direct clinical drug use of patients and select new drugs by high throughput screening.

5. Your company’s projects have lots of internationally cutting-edge technologies. What hardware and software (research and development personnel) do your company have to support the technical development and application?

Under the support of the Government of Licang District, we have set up an advanced experiment center of chemistry, cell biology and molecular biology. At present, the experiment center has set up a joint laboratory with the University of Waterloo and Qilu University of Technology (Shandong Academy of Sciences) and built partnerships with local colleges and universities in Qingdao. At present, we have 20 research and development personnel. At the end of this year, our research and development team will have 35 persons including 15 doctors and 10 overseas talents. 

6. Will your company apply to be listed on the sci-tech innovation board?

It is the trend and what the sci-tech innovation board hopes. 

The person in charge of the project exhibited Academician Chen Pu’s projects on site. 

The promotion conference also invited Peng Dan, vice president of Xiangrong (Shanghai) Biotechnology Co., Ltd., who provided information on the development and prospect of the biopharmaceutical industry in China, spoke highly of Academician Chen Pu’s research results and was confident in future development. Multiple enterprise attendees showed a strong interest in high-tech high-value-added project products, were full of confidence in the prospects of project development and actively sought for cooperation opportunities. During the promotion conference, Zhang Ke’an, general manager of Qingdao Yida Biotech Co., Ltd., Li Shaowen from Qingdao TC-Norder Biotechnology Co., Ltd. and Academician Chen Pu discussed the product application and future market development. 

The promotion conference also invited Peng Dan, vice president of Xiangrong (Shanghai) Biotechnology Co., Ltd., who provided information on the development and prospect of the biopharmaceutical industry in China, spoke highly of Academician Chen Pu’s research results and was confident in future development. Multiple enterprise attendees showed a strong interest in high-tech high-value-added project products, were full of confidence in the prospects of project development and actively sought for cooperation opportunities. During the promotion conference, Zhang Ke’an, general manager of Qingdao Yida Biotech Co., Ltd., Li Shaowen from Qingdao TC-Norder Biotechnology Co., Ltd. and Academician Chen Pu discussed the product application and future market development. 

Qingdao International Academician Park devotes itself to building an academician-led distinctive platform for high-end technical innovation and industrialization, focuses on new energy and materials, life health, biopharmaceuticals, information technology, design and R&D, high-end equipment manufacturing, etc., highlights the development direction of high-grade, precision, advanced and scarce products and invites global well-known academicians to carry out scientific research and commercialize results. At present, it has signed contracts with 108 academicians and 85% of them are foreign academicians. 32 academician projects have been carried out and 13 of them have yielded 38 products. It strives to build industrial chains and clusters with the annual output value of 10 billion yuan or 100 billion yuan.